Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE Immunotherapeutics (PAR: OSE) and partner Veloxis Pharmaceuticals announce ODD for VEL-101
Published by Arron Aatkar, PhD

OSE Immunotherapeutics, and its partner Veloxis Pharmaceuticals, have announced receipt of orphan drug designation (ODD) for VEL-101, which is in clinical development as a potential maintenance therapy for patients following kidney transplantation. This has several development and commercial advantages, including: tax credits for qualified clinical trials; exemption from user fees; and the potential for seven years of market exclusivity after approval. While this is a positive milestone, we note that Veloxis is responsible for the programme and, therefore, OSE has little control over how it runs.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.